Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Multi-institutional researchers have succeeded in efficiently delivering an immune checkpoint inhibitor (ICI) into the mouse brain, confirming its high efficacy and specificity in treating orthotopically transplanted mice with glioblastoma (GBM). The research was published in Nature Biomedical Engineering.
Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues.
A team led by researchers at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School, Massachusetts General Hospital and the Broad Institute of MIT and Harvard has profiled in unprecedented detail thousands of individual cells sampled from patients' brain tumors.
Gliomas are the most common primary brain tumors in adults. Among them, high-grade glioblastomas (GBMs) are particularly known to be notoriously aggressive and invasive, which makes it challenging to treat them.
A new study reports the use of single-cell, force spectroscopy methods to probe biophysical and biomechanical kinetics of cancer cells.
Oncotarget published "Dynamic cellular biomechanics in responses to chemotherapeutic drug in hypoxia probed by atomic force spectroscopy" which reported that by exploiting single-cell, force spectroscopy methods, the authors probed biophysical and biomechanical kinetics of brain, breast, prostate, and pancreatic cancer cells with standard chemotherapeutic drugs in normoxia and hypoxia over 12-24 hours.
A promising treatment for melanoma and other types of cancers is neoadjuvant immune checkpoint blockade (ICB).
Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted by natural killer (NK) cells, they are able to evade immune attack by releasing the TFG-β signaling protein, which blocks NK cell activity.
Scientists have come up with an innovative function for the metabolic enzyme medium-chain acyl-CoA dehydrogenase (MCAD) in glioblastoma (GBM).
In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming drug resistance a major goal in cancer research.
The research group led by Dr Sjoerd van Wijk from the Institute of Experimental Cancer Research in Paediatrics at Goethe University already two years ago found evidence indicating that the anti-diarrhea drug loperamide could be used to induce cell death in glioblastoma cell lines.
One of the hallmarks of Glioblastoma (GBM), the most aggressive type of brain cancer, is its high invasive capacity, which leads to its expansion into the normal brain tissue.
Researchers at Tel Aviv University have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers.
Scientists have designed a new targeted therapy, known as POMHEX, which inhibits vital metabolic pathways in tumor cells containing specific genetic defects.
Researchers have shown that the advanced CRISPR/Cas9 system is extremely effective in curing metastatic cancers.
Researchers have designed a laboratory test that can precisely examine the deadliest cells found in the most common and aggressive type of brain cancer.
Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.
Australian researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.
New insight into a gene that controls energy production in cancer stem cells could help in the search for a more effective treatment for glioblastoma.
The multiplication of genes located in extrachromosomal DNA that have the potential to cause cancer drives poor patient outcomes across many cancer types, according to a Nature Genetics study published Aug. 17, 2020 by a team of researchers including Professors Vineet Bafna and Dr.Paul Mischel of the University of California San Diego and Professor Roel Verhaak of Jackson Laboratories.